Study on the efficacy of Edaravone in treatment of idiopathic pulmonary fibrosis

Objective To explore the clinical efficacy and safety of Edaravone in treatment of idiopathic pulmonary fibrosis. Methods A total of 85 patients with idiopathic pulmonary fibrosis during June 2010 to June 2013 were allocated in this study,they were randomly divided into control group( conventional treatment group,n = 42 cases) and trial group( conventional treatment plus Edaravone,n = 43 cases). The blood oxygen partial pressure,amount of ventilation,serum level of TGI-beta 1 and amount of carbon monoxide diffusion were examined and compared between these 2 groups in order to determine the curative effect of patients in these two groups. Results The blood oxygen partial pressure and amount of carbon monoxide diffusion in patients of these 2 groups were significantly increased compared with those before treatment,but the degree of increase in trial group was bigger than that of control group,and the difference was significant( P 0. 01). The improvement in serum level of TGF-beta 1 and ventilation condition in patients of trial group was more significant than those of patients in control group,and the difference was statistically significant( P 0. 05). The serum level of TGF-beta 1 was dropped,and ventilation was increased in patients of these 2 groups.The curative effect and total effective rate of patients in trial group were higher than those of patients in control group,and the difference was statistically significant( P 0. 05). There was no difference in occurrence of adverse reactions between patients of two groups( P 0. 05). Conclusion On the basis of conventional treatment,the application of Edaravone in treatment of patients with idiopathic pulmonary fibrosis can achieve good clinical curative effect with good safety,it is worthy to be clinically popularized and applied.